Loading
Randomise people through the national health system, post the blood kit, and read cancer deaths off the registry. That is ten times cheaper per participant than a classic trial.
Swedish registry-based RCTs (TASTE, DETO2X) showed pragmatic randomisation at national scale at a fraction of usual cost. Propose an MCED trial that randomises through screening call/recall, draws blood at existing phlebotomy or mobile units, and uses cancer registry and death-certificate linkage for endpoints, with no in-person study visits.
One bottleneck page and 32 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
NHS-Galleri is the trial that will decide whether a blood test for many cancers at once should be offered by a health system. Its endpoint is a reduction in late-stage cancer rather than deaths, so even a positive result leaves the mortality question to be settled by longer follow-up.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test, Stage shift, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, Stage shift, The hardest cancers are found late.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late.